Zanaflex Capsule
Product Images NDC 73352-090

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Zanaflex (NDC 73352-090). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Trifluent Pharma, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image Description (Zanaflex Label V1)

Image Description (Zanaflex Label V1)
This text provides information about Zanaflex® capsules containing 9.16 mg of tizanidine hydrochloride, equivalent to 8 mg of tizanidine base. It suggests referring to the package insert for prescribing information and storing the capsules at 20°C to 25°C. It emphasizes keeping the medication out of reach of children and dispenses in child-resistant containers. The text also mentions that Zanaflex® is a registered trademark of Legacy Pharma Inc. The capsules are not interchangeable with tizanidine or Zanaflex tablets. It indicates that the product is distributed by Trifluent Pharma, LLC in San Antonio, TX. Additionally, it provides the National Drug Code (NDC) for the capsules and relevant coding details.*
FDA Label Image

Image Description (Zan01 0001 01a)

Image Description (Zan01 0001 01a)
FDA Label Image

Image Description (Zan01 0001 02a)

Image Description (Zan01 0001 02a)
FDA Label Image

Image Description (Zan01 0001 03a)

Image Description (Zan01 0001 03a)
This text describes the improvement in Ashworth Score over time for two doses of tizanidine (8 mg and 16 mg) as measured in hours post-dose.*
FDA Label Image

Image Description (Zan01 0001 04a)

Image Description (Zan01 0001 04a)
This text appears to be describing the improvement in Ashworth Score with Tizanidine at a mean dose of 26.8 mg compared to a placebo. It mentions different study weeks and the titration and maintenance endpoint for the assessment.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.